| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID3941 Maralixibat for treating cholestatic pruritus in Alagille syndrome |
|
Medicine details |
|
| Medicine name | maralixibat (Livmarli) |
| Formulation | 9.5 mg/ml oral solution |
| Reference number | 3215 |
| Indication | Treatment of cholestatic pruritus in Alagille syndrome |
| Company | Mirum Pharmaceuticals |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/11/2024 |
| NICE guidance | ID3941 Maralixibat for treating cholestatic pruritus in Alagille syndrome |